price apr usd
revenu usdm
hold rate reflect view see less room upsid
ep estim multipl expans versu peer given believ
rel mute margin expans opportun lack notabl product cycl
drive revenu acceler result compani meaning
miss ours/street estim lower guidanc support thesi
thing like
india return growth sever quarter weak india
report mid-singl digit growth even better perform
liquid chromatographi pharma market manag note cautiou
optim continu improv trend india
thing cautiou
 ep organ sale growth miss flat organ sale growth
came meaning estim consensu
cite sever factor miss includ softer demand china europ
also note instrument sale declin adjust ep
also meaning miss dbe/consensu forecast
lower guid guid lower organ sale
growth guidanc rang reflect macro
headwind china europ well slower-than-expect pace
capit budget releas pharma industri custom compani
also lower adjust ep guidanc rang
 mid-point guidanc also came dbe
consensu compani expect take time
headwind abat
 china headwind caus concern minim visibl turnaround
time view headwind china sale declin
one key driver under-perform lower
outlook china headwind driven nation bulk drug
procur program place pressur chines gener drug
manufactur impact capit spend reorgan
china food ministri expect china trend improv
throughout believ forward visibl limit particularli
deutsch bank seek busi compani cover research report thu investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis disclosur analyst certif locat
distribut gmt
around nation drug tender program inde program remain
focu chines govern
 europ macro headwind drove declin europ sale declin
reflect macro uncertainti constrain spend among
biopharma industri custom inde manag note
headwind relat brexit uncertainti western europ
market sale flat y/i repres materi deceler
growth report dec-qtr slowdown reflect
aforement headwind china well slower-than-expect
begin year budget releas larg pharma custom
posit side biolog custom demand remain healthi
manag expect gradual improv end market
cours year
lower pt
lower pt reflect lower ebitda
forecast follow result pt reflect enterpris valu use
project level debt cash ebitda ex option forecast
trail twelv month end multipl discount life
scienc tool peer group median ev/ftm ebitda ex option think
reason given secular growth prospect limit margin expans
period end incom expens ep share share sale cash flowoper cash cash constant
period end asset equival st receiv expens current current equip asset asset liabil current portion long-term current debt less current long-term liabil stockhold april
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur primari
subject research pleas see recent publish compani report visit global disclosur look-up page websit http //research db com/research/disclosures/
companysearch asid within report import risk conflict disclosur also found investor
strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
import disclosur requir non-u regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
